Cargando…

Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Methods. Recommendations were established via consensus by a panel of experts in rheumatology and hospital phar...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Álvaro, Isidoro, Martínez-Fernández, Carmen, Dorantes-Calderón, Benito, García-Vicuña, Rosario, Hernández-Cruz, Blanca, Herrero-Ambrosio, Alicia, Ibarra-Barrueta, Olatz, Martín-Mola, Emilio, Monte-Boquet, Emilio, Morell-Baladrón, Alberto, Sanmartí, Raimon, Sanz-Sanz, Jesús, de Toro-Santos, Francisco Javier, Vela, Paloma, Román Ivorra, José Andrés, Poveda-Andrés, José Luis, Muñoz-Fernández, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4473767/
https://www.ncbi.nlm.nih.gov/pubmed/25526976
http://dx.doi.org/10.1093/rheumatology/keu461
_version_ 1782377225712041984
author González-Álvaro, Isidoro
Martínez-Fernández, Carmen
Dorantes-Calderón, Benito
García-Vicuña, Rosario
Hernández-Cruz, Blanca
Herrero-Ambrosio, Alicia
Ibarra-Barrueta, Olatz
Martín-Mola, Emilio
Monte-Boquet, Emilio
Morell-Baladrón, Alberto
Sanmartí, Raimon
Sanz-Sanz, Jesús
de Toro-Santos, Francisco Javier
Vela, Paloma
Román Ivorra, José Andrés
Poveda-Andrés, José Luis
Muñoz-Fernández, Santiago
author_facet González-Álvaro, Isidoro
Martínez-Fernández, Carmen
Dorantes-Calderón, Benito
García-Vicuña, Rosario
Hernández-Cruz, Blanca
Herrero-Ambrosio, Alicia
Ibarra-Barrueta, Olatz
Martín-Mola, Emilio
Monte-Boquet, Emilio
Morell-Baladrón, Alberto
Sanmartí, Raimon
Sanz-Sanz, Jesús
de Toro-Santos, Francisco Javier
Vela, Paloma
Román Ivorra, José Andrés
Poveda-Andrés, José Luis
Muñoz-Fernández, Santiago
author_sort González-Álvaro, Isidoro
collection PubMed
description Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Methods. Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists. Results. Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases. Conclusion. The recommendations established herein aim not only to provide advice on how to improve the risk:benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases.
format Online
Article
Text
id pubmed-4473767
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44737672015-06-24 Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis González-Álvaro, Isidoro Martínez-Fernández, Carmen Dorantes-Calderón, Benito García-Vicuña, Rosario Hernández-Cruz, Blanca Herrero-Ambrosio, Alicia Ibarra-Barrueta, Olatz Martín-Mola, Emilio Monte-Boquet, Emilio Morell-Baladrón, Alberto Sanmartí, Raimon Sanz-Sanz, Jesús de Toro-Santos, Francisco Javier Vela, Paloma Román Ivorra, José Andrés Poveda-Andrés, José Luis Muñoz-Fernández, Santiago Rheumatology (Oxford) Clinical Science Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Methods. Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists. Results. Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases. Conclusion. The recommendations established herein aim not only to provide advice on how to improve the risk:benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases. Oxford University Press 2015-07 2014-12-19 /pmc/articles/PMC4473767/ /pubmed/25526976 http://dx.doi.org/10.1093/rheumatology/keu461 Text en © The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
González-Álvaro, Isidoro
Martínez-Fernández, Carmen
Dorantes-Calderón, Benito
García-Vicuña, Rosario
Hernández-Cruz, Blanca
Herrero-Ambrosio, Alicia
Ibarra-Barrueta, Olatz
Martín-Mola, Emilio
Monte-Boquet, Emilio
Morell-Baladrón, Alberto
Sanmartí, Raimon
Sanz-Sanz, Jesús
de Toro-Santos, Francisco Javier
Vela, Paloma
Román Ivorra, José Andrés
Poveda-Andrés, José Luis
Muñoz-Fernández, Santiago
Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
title Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
title_full Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
title_fullStr Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
title_full_unstemmed Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
title_short Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
title_sort spanish rheumatology society and hospital pharmacy society consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4473767/
https://www.ncbi.nlm.nih.gov/pubmed/25526976
http://dx.doi.org/10.1093/rheumatology/keu461
work_keys_str_mv AT gonzalezalvaroisidoro spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT martinezfernandezcarmen spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT dorantescalderonbenito spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT garciavicunarosario spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT hernandezcruzblanca spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT herreroambrosioalicia spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT ibarrabarruetaolatz spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT martinmolaemilio spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT monteboquetemilio spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT morellbaladronalberto spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT sanmartiraimon spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT sanzsanzjesus spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT detorosantosfranciscojavier spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT velapaloma spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT romanivorrajoseandres spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT povedaandresjoseluis spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis
AT munozfernandezsantiago spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis